MA45172B1 - Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées - Google Patents

Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées

Info

Publication number
MA45172B1
MA45172B1 MA45172A MA45172A MA45172B1 MA 45172 B1 MA45172 B1 MA 45172B1 MA 45172 A MA45172 A MA 45172A MA 45172 A MA45172 A MA 45172A MA 45172 B1 MA45172 B1 MA 45172B1
Authority
MA
Morocco
Prior art keywords
modified rna
formulations
polypeptides
rna encoding
encoding vegf
Prior art date
Application number
MA45172A
Other languages
English (en)
Other versions
MA45172A (fr
Inventor
Leif Karlsson Parinder
Danielson Regina Desirée Fritsche
Kenny Mikael Hansson
Li Ming Gan
Jonathan Clarke
Ann-Charlotte Eva Egnell
Kenneth Randall Chien
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of MA45172A publication Critical patent/MA45172A/fr
Publication of MA45172B1 publication Critical patent/MA45172B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules d'arn modifiées codant pour des polypeptides vegf-a et des formulations comprenant l'arn modifié. Des aspects de l'invention concernent en outre des préparations et des utilisations de formulations comprenant l'arn modifié dans le traitement de sujets souffrant de maladies sensibles à une thérapie par vegf-a.
MA45172A 2016-06-07 2017-06-06 Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées MA45172B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346979P 2016-06-07 2016-06-07
US201662411091P 2016-10-21 2016-10-21
US201662432005P 2016-12-09 2016-12-09
PCT/US2017/036188 WO2017214175A1 (fr) 2016-06-07 2017-06-06 Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées

Publications (2)

Publication Number Publication Date
MA45172A MA45172A (fr) 2019-04-10
MA45172B1 true MA45172B1 (fr) 2021-11-30

Family

ID=59270113

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45172A MA45172B1 (fr) 2016-06-07 2017-06-06 Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées

Country Status (25)

Country Link
US (1) US11866475B2 (fr)
EP (2) EP3971204A1 (fr)
JP (3) JP6859369B2 (fr)
KR (4) KR102494499B1 (fr)
CN (2) CN116606861A (fr)
AU (2) AU2017277277B2 (fr)
CA (1) CA3026500A1 (fr)
CY (1) CY1124667T1 (fr)
DK (1) DK3464338T3 (fr)
ES (1) ES2895421T3 (fr)
HR (1) HRP20211569T1 (fr)
HU (1) HUE056055T2 (fr)
IL (1) IL263370A (fr)
LT (1) LT3464338T (fr)
MA (1) MA45172B1 (fr)
MX (1) MX2018015110A (fr)
PL (1) PL3464338T3 (fr)
PT (1) PT3464338T (fr)
RS (1) RS62556B1 (fr)
RU (1) RU2756313C2 (fr)
SG (2) SG11201810816QA (fr)
SI (1) SI3464338T1 (fr)
SM (1) SMT202100586T1 (fr)
TW (2) TWI752036B (fr)
WO (1) WO2017214175A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3971204A1 (fr) 2016-06-07 2022-03-23 Modernatx, Inc. Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
WO2019010304A1 (fr) * 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Microparticules enrobées de minéraux pour l'administration de gènes dans une thérapie de plaie chronique
DK3703658T3 (da) 2017-10-31 2022-07-18 Astrazeneca Ab Lipidnanopartikler til administration af modificeret rna, der koder for et vegf-a-polypeptid
US20220226243A1 (en) * 2019-05-08 2022-07-21 Astrazeneca Ab Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same
JP7345888B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
WO2023061985A2 (fr) * 2021-10-12 2023-04-20 Modernatx, Inc. Compositions comprenant un arn modifié codant pour vegf-a et procédés d'utilisation
WO2023084013A1 (fr) * 2021-11-12 2023-05-19 Modernatx, Inc. Compositions comprenant un arn modifié codant vegf-a et méthodes d'utilisation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004035227A1 (de) * 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
CA2597329C (fr) 2005-02-08 2016-10-11 Board Of Regents, The University Of Texas System Compositions et methodes faisant intervenir la proteine mda-7 pour le traitement du cancer
EP2367432B1 (fr) 2008-12-03 2017-08-30 Amorcyte, Inc. Composition améliorant la perfusion d'une zone d'infarctus
MX2011005912A (es) * 2008-12-04 2011-06-17 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor de crecimiento endotelial vascular por inhibicion de transcrito antisentido natural para factor de crecimiento endotelial vascular.
WO2011069529A1 (fr) * 2009-12-09 2011-06-16 Curevac Gmbh Solution contenant du mannose pour la lyophilisation, la transfection et/ou l'injection d'acides nucléiques
CA2821622C (fr) 2010-12-16 2019-09-03 Sprna Gmbh Composition pharmaceutique a base d'arn qui comprend un metal alcalin en tant que contre-ion et formule avec des dications
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
JP2014511694A (ja) * 2011-04-03 2014-05-19 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
CN104968354A (zh) 2011-12-21 2015-10-07 现代治疗公司 增加器官或器官外植体的活力或寿命的方法
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
WO2013151663A1 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés pour la production de protéines membranaires
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US10258698B2 (en) * 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
AU2014310933B2 (en) * 2013-08-21 2020-05-14 CureVac SE Method for increasing expression of RNA-encoded proteins
EP3835318B1 (fr) * 2014-01-15 2025-10-29 F. Hoffmann-La Roche AG Variants de région fc à fcrn modifié et propriétés de ligand a protéique maintenues
EP3247398A4 (fr) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Compositions de nanoparticules lipidiques
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
EP3971204A1 (fr) 2016-06-07 2022-03-23 Modernatx, Inc. Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
US11542490B2 (en) 2016-12-08 2023-01-03 CureVac SE RNAs for wound healing
MX389934B (es) 2016-12-09 2025-03-20 Desarrolladora Y Com De Tecnologias Biomedicas Decotecbio S A De C V Composición coadyuvante de un factor de crecimiento y un neuropéptido para acelerar la cicatrización de heridas y la repitelización de órganos.
DK3703658T3 (da) 2017-10-31 2022-07-18 Astrazeneca Ab Lipidnanopartikler til administration af modificeret rna, der koder for et vegf-a-polypeptid
CN114375190A (zh) 2019-05-08 2022-04-19 阿斯利康(瑞典)有限公司 用于皮肤和伤口的组合物及其使用方法

Also Published As

Publication number Publication date
HUE056055T2 (hu) 2022-01-28
CN109790207B (zh) 2023-06-20
JP6859369B2 (ja) 2021-04-14
RU2756313C2 (ru) 2021-09-29
WO2017214175A1 (fr) 2017-12-14
KR102494499B1 (ko) 2023-01-31
CN116606861A (zh) 2023-08-18
RU2018147229A (ru) 2020-07-10
US20200407411A1 (en) 2020-12-31
KR20220038819A (ko) 2022-03-29
JP7167226B2 (ja) 2022-11-08
EP3971204A1 (fr) 2022-03-23
SG11201810816QA (en) 2018-12-28
IL263370A (en) 2018-12-31
KR102552543B1 (ko) 2023-07-06
CY1124667T1 (el) 2022-07-22
LT3464338T (lt) 2022-01-10
AU2017277277B2 (en) 2023-05-04
AU2017277277A1 (en) 2019-01-03
SMT202100586T1 (it) 2021-11-12
JP2023011733A (ja) 2023-01-24
PL3464338T3 (pl) 2021-12-27
US11866475B2 (en) 2024-01-09
MA45172A (fr) 2019-04-10
HRP20211569T1 (hr) 2022-01-21
TWI818375B (zh) 2023-10-11
AU2023208200A1 (en) 2023-08-17
PT3464338T (pt) 2021-10-19
MX2018015110A (es) 2019-09-06
DK3464338T3 (da) 2021-10-18
CA3026500A1 (fr) 2017-12-14
JP2019521976A (ja) 2019-08-08
JP2021100961A (ja) 2021-07-08
KR20190039066A (ko) 2019-04-10
KR20230019505A (ko) 2023-02-08
KR102376245B1 (ko) 2022-03-21
TW201808325A (zh) 2018-03-16
ES2895421T3 (es) 2022-02-21
RU2018147229A3 (fr) 2020-09-23
RS62556B1 (sr) 2021-12-31
TWI752036B (zh) 2022-01-11
EP3464338B1 (fr) 2021-07-21
CN109790207A (zh) 2019-05-21
KR20230107891A (ko) 2023-07-18
EP3464338A1 (fr) 2019-04-10
TW202218670A (zh) 2022-05-16
SG10202012175YA (en) 2021-01-28
SI3464338T1 (sl) 2022-02-28

Similar Documents

Publication Publication Date Title
MY196882A (en) Recombinant binding proteins and their use
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
MA38478A1 (fr) Anticorps anti-pac1 humains
EA201992607A1 (ru) Твердые формы берберина урсодезоксихолата, их композиции и способы
CR20200196A (es) Proteínas trispecìficas y mètodos de uso
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
CY1124667T1 (el) Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
MA41010A (fr) Compositions comprenant des souches bactériennes
EA201792047A1 (ru) Новые соединения
WO2017134302A3 (fr) Agents thérapeutiques ciblés et leurs utilisations
MA35507B1 (fr) Protéines à double fonction pour le traitement de troubles du métabolisme
MA39390B2 (fr) Thérapie génique pour le traitement de la rétinite pigmentaire
MA39342B2 (fr) Anticorps il -21
MA44426B1 (fr) Compositions et méthodes pour diminier l'expression de tau
MX2017014730A (es) Muteinas de lipocalina 2 humana con afinidad por glipicano-3 (gpc3).
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
EP3492096A4 (fr) Composition pharmaceutique pour le traitement de maladies oculaires, contenant une protéine cas9 et un arn guide
EA202092305A1 (ru) Соединения в качестве модуляторов сигнализации tlr2
MA38485A1 (fr) Anticorps anti-cd52 humains pour une utilisation dans le traitement, par exemple, des maladies auto-immunes, le cancer, et le rejet de greffe
EA201992688A1 (ru) Средства, пути применения и способы лечения